申请人:Santhera Pharmaceuticals (Schweiz) AG
公开号:EP2072516A1
公开(公告)日:2009-06-24
The present invention relates to substituted imidazopyridine derivatives as melanocortin-4 receptor (MC-4R) modulators, in particular as melanocortin 4 receptor antagonists. The antagonists are useful for the treatment of disorders and diseases such as cancer cachexia, muscle wasting, anorexia, anxiety and depression.
本发明涉及取代咪唑吡啶衍生物作为黑色素皮质素-4受体(MC-4R)调节剂,特别是作为黑色素皮质素4受体拮抗剂。这些拮抗剂对于治疗癌症恶病质、肌肉萎缩、厌食、焦虑和抑郁等疾病和疾病非常有用。